

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM353777

| | |
|------------------------------|--------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | Security Agreement |
| SEQUENCE: | 2 |

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|-----------------------------------|----------|----------------|-----------------------|
| Clinical Research Advantage, Inc. | | 08/18/2015 | CORPORATION: ARIZONA |
| CNS Research Science, Inc. | | 08/18/2015 | CORPORATION: DELAWARE |
| Radiant Research, Inc. | | 08/18/2015 | CORPORATION: DELAWARE |
| Pharmaco Investements, Inc. | | 08/18/2015 | CORPORATION: DELAWARE |
| Acurian, Inc. | | 08/18/2015 | CORPORATION: DELAWARE |

RECEIVING PARTY DATA

| | |
|------------------------|--|
| Name: | CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent |
| Street Address: | 11 Madison Avenue |
| City: | New York |
| State/Country: | NEW YORK |
| Postal Code: | 10010 |
| Entity Type: | CORPORATION: NEW YORK |

PROPERTY NUMBERS Total: 45

| Property Type | Number | Word Mark |
|-----------------------------|---------|--------------------------------|
| Registration Number: | 3637316 | CLINICAL RESEARCH ADVANTAGE |
| Registration Number: | 3597155 | CLINICAL RESEARCH ADVANTAGE |
| Registration Number: | 3431297 | CNS |
| Registration Number: | 3431298 | CNS |
| Registration Number: | 3431299 | CNS |
| Registration Number: | 3431300 | CNS |
| Registration Number: | 3966684 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3962188 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3962189 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3962190 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3966685 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 4084213 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3449533 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3449534 | CNS COMPREHENSIVE NEUROSCIENCE |

TRADEMARK

| Property Type | Number | Word Mark |
|----------------------|----------|--|
| Registration Number: | 3449535 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3449536 | CNS COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 4156802 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 4156803 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 4156804 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 4155886 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 4148011 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 4155887 | COMPREHENSIVE CLINICAL DEVELOPMENT |
| Registration Number: | 3500478 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3500479 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3500480 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3500481 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3500482 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 3500483 | COMPREHENSIVE NEUROSCIENCE |
| Registration Number: | 2511395 | RADIANT RESEARCH |
| Registration Number: | 2136203 | CG++ |
| Registration Number: | 2084758 | CROSSGRAPHS |
| Registration Number: | 2435414 | PPD |
| Registration Number: | 2332213 | PPD |
| Registration Number: | 2644316 | PPD QUERYDIRECT |
| Registration Number: | 2179522 | TABLETRANS |
| Registration Number: | 4573756 | PRECLARUS |
| Registration Number: | 3971039 | ACURIAN RECRUITMENT MANAGER |
| Registration Number: | 3723631 | YOUR PATIENTS HOLD THE PROMISE FOR TOMOR |
| Registration Number: | 3819261 | CLICK IT FORWARD |
| Registration Number: | 2697439 | ACURIAN |
| Registration Number: | 2566246 | ACURIAN |
| Registration Number: | 4411824 | ACURIAN HEALTH |
| Registration Number: | 4429550 | |
| Registration Number: | 4621574 | ACURIAN RETENTION MANAGER |
| Serial Number: | 86303607 | TRIMENTUM |

CORRESPONDENCE DATA

Fax Number: 8668265420

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 301-638-0511

Email: ipresearchplus@comcast.net

Correspondent Name: IP Research Plus, Inc.

Address Line 1: 21 Tadcaster Circle

TRADEMARK

REEL: 005615 FRAME: 0527

Address Line 2: attn: Penelope J.A. Agodoa
Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER: CRS1-40389

NAME OF SUBMITTER: Penelope J.A. Agodoa

SIGNATURE: /pja/

DATE SIGNED: 09/02/2015

Total Attachments: 11
source=40389#page1.tif
source=40389#page2.tif
source=40389#page3.tif
source=40389#page4.tif
source=40389#page5.tif
source=40389#page6.tif
source=40389#page7.tif
source=40389#page8.tif
source=40389#page9.tif
source=40389#page10.tif
source=40389#page11.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (as amended, amended and restated, supplemented or otherwise modified from time to time, the "IP Security Agreement") dated August 18, 2015, is among the Persons listed on the signature pages hereof (collectively, the "Grantors") and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as collateral agent (the "Collateral Agent") for the Secured Parties (as defined in the Credit Agreement referred to below).

WHEREAS, Jaguar Holding Company I, a Delaware corporation, Jaguar Holding Company II, a Delaware corporation, and Pharmaceutical Product Development, LLC, a Delaware limited liability company, have entered into the Credit Agreement dated as of August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), with the Lenders, the L/C Issuers and the Administrative Agent. Capitalized terms defined in the Credit Agreement or in the Security Agreement (as defined below) and not otherwise defined herein are used herein as defined in the Credit Agreement or the Security Agreement, as the case may be (and in the event of a conflict, the applicable definition shall be the one given to such term in the Security Agreement).

WHEREAS, as a condition precedent to the making of the Loans by the Lenders from time to time and the issuance of Letters of Credit by the L/C Issuers from time to time, the entry into Secured Hedge Agreements by the Hedge Banks from time to time and the entry into Secured Cash Management Agreements by the Cash Management Banks from time to time, each Grantor has executed and delivered that certain Security Agreement dated August 18, 2015 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Security Agreement"), among the Grantors from time to time party thereto and the Collateral Agent.

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed thereunder to execute this IP Security Agreement for recording with the USPTO and/or the USCO, as applicable.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

Section 1. Grant of Security. Each Grantor hereby collaterally assigns and pledges to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, and each Grantor hereby grants to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a security interest in all of such Grantor's right, title and interest in and to the following, whether now owned or hereafter acquired by the undersigned (the "Collateral"):

(i) the patents and patent applications set forth in Schedule A hereto (the "Patents");

(ii) the trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and so long as creation of a security interest therein or the assignment thereof would result in the loss of any material rights therein), together with the goodwill symbolized thereby (the "Trademarks");

(iii) all copyrights, whether registered or unregistered, including, without limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto (the “Copyrights”);

(iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing;

provided that notwithstanding anything to the contrary contained in the foregoing clauses (i) through (vi), the security interest created hereby shall not extend to, and the term “Collateral” shall not include, any Excluded Assets.

Section 2. Security for Obligations. The grant of a security interest in, the Collateral by each Grantor under this IP Security Agreement secures the payment of all Secured Obligations of such Grantor now or hereafter existing under or in respect of the Secured Documents (as such Secured Documents may be amended, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time (including any increases of the principal amount outstanding thereunder)), whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise. Without limiting the generality of the foregoing, this IP Security Agreement secures, as to each Grantor, the payment of all amounts that constitute part of the Secured Obligations that would be owed by such Grantor to any Secured Party under the Secured Documents but for the fact that they are unenforceable or not allowable due to the existence of a bankruptcy, or reorganization or similar proceeding involving a Loan Party.

Section 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks record this IP Security Agreement.

Section 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

Section 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this IP Security Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall govern.

Section 6. Governing Law; Jurisdiction; Etc. (a) THIS IP SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO THE CONFLICTS OF LAWS PRINCIPLES THEREOF, BUT INCLUDING SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW.

(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY IN THE BOROUGH OF MANHATTAN AND OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SITTING IN THE BOROUGH OF MANHATTAN, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS IP SECURITY AGREEMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, THE COLLATERAL AGENT, ANY LENDER OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS IP SECURITY AGREEMENT OR THE RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT AGAINST ANY LOAN PARTY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

(c) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS IP SECURITY AGREEMENT IN ANY COURT REFERRED TO IN PARAGRAPH (b) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.


(d) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE CREDIT AGREEMENT. NOTHING IN THIS IP SECURITY AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

(e) EACH PARTY TO THIS IP SECURITY AGREEMENT HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS IP SECURITY AGREEMENT OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS IP SECURITY AGREEMENT, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER


FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY, AND THAT ANY PARTY TO THIS IP SECURITY AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 6(e) WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE SIGNATORIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this IP Security Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first written above.

**PHARMACEUTICAL PRODUCT
DEVELOPMENT, LLC**


By: 
Name: B. Judd Hartman
Title: General Counsel and Secretary

**ACURIAN, INC.
CLINICAL RESEARCH ADVANTAGE, INC.
CNS RESEARCH SCIENCE, INC.
RADIANT RESEARCH, INC.**


By: 
Name: B. Judd Hartman
Title: General Counsel and Secretary

PPD DEVELOPMENT, L.P.


By: PPD GP, LLC, its general partner

By: 
Name: B. Judd Hartman
Title: Vice President, General Counsel and Secretary

X-CHEM, INC.

By: 
Name: B. Judd Hartman
Title: Vice President, General Counsel and Secretary

PHARMACO INVESTMENTS, INC.

By: 
Name: B. Judd Hartman
Title: President and Secretary

**CREDIT SUISSE AG, CAYMAN ISLANDS
BRANCH**
as Collateral Agent

By: _____
Name: **NUPUR KUMAR**
Title: **AUTHORIZED SIGNATORY**

By: _____
Name: **WHITNEY GASTON**
Title: **AUTHORIZED SIGNATORY**

Schedule A

Registered Patents

| Owner | Registration Number | Expiration Date |
|--|---------------------|-----------------|
| Pharmaceutical Product Development, LLC | 7,934,434 B2 | Sept. 27, 2029 |
| PPD Development, L.P. | 6,507,829 | Jan. 17, 2020 |
| Pharmaco Investments, Inc. | 8,790,599 | Jul. 14, 2031 |
| Pharmaco Investments, Inc. and Duke University | 6,191,147 | Nov. 15, 2019 |
| Pharmaco Investments, Inc. | 6,649,638 | Aug. 14, 2022 |
| Pharmaco Investments, Inc. | 6,664,277 | Aug. 14, 2022 |
| Pharmaco Investments, Inc. | 7,112,596 | Aug. 14, 2022 |
| Pharmaco Investments, Inc. | 7,501,444 | Nov. 19, 2022 |
| Pharmaco Investments, Inc. | 7,501,446 | Aug. 14, 2022 |
| Pharmaco Investments, Inc. | 8,669,253 | Mar. 14, 2029 |


Patent Applications

| Owner | Application Number | Expiration Date |
|--------------|--------------------|-----------------|
| X-Chem, Inc. | 61/152,508 | N/A |
| X-Chem, Inc. | 13/147,910 | N/A |
| X-Chem, Inc. | 61/531,820 | N/A |
| X-Chem, Inc. | 61/536,929 | N/A |
| X-Chem, Inc. | 14/343,306 | N/A |
| X-Chem, Inc. | 61/584,593 | N/A |
| X-Chem, Inc. | 61/584,569 | N/A |
| X-Chem, Inc. | 61/671,406 | N/A |
| X-Chem, Inc. | 14/370,854 | N/A |
| X-Chem, Inc. | 61/715,116 | N/A |
| X-Chem, Inc. | 14/370,879 | N/A |
| X-Chem, Inc. | 61/901,899 | N/A |
| X-Chem, Inc. | 62/043,275 | N/A |
| X-Chem, Inc. | 14/414,326 | N/A |
| X-Chem, Inc. | 62/098,037 | N/A |

Schedule B

Registered Trademarks

| Owner | Mark | Registration Number | Expiration Date |
|-----------------------------------|--|---------------------|-----------------|
| Clinical Research Advantage, Inc. | CLINICAL RESEARCH ADVANTAGE | 3637316 | Jun. 16, 2019 |
| Clinical Research Advantage, Inc. | CLINICAL RESEARCH ADVANTAGE | 3597155 | Mar. 31, 2019 |
| CNS Research Science, Inc. | CNS | 3431297 | May 20, 2018 |
| CNS Research Science, Inc. | CNS | 3431298 | May 20, 2018 |
| CNS Research Science, Inc. | CNS | 3431299 | May 20, 2018 |
| CNS Research Science, Inc. | CNS | 3431300 | May 20, 2018 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3966684 | Aug. 24, 2021 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3962188 | May 17, 2021 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3962189 | May 17, 2021 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3962190 | May 17, 2021 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3966685 | May 24, 2021 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 4084213 | Jan. 10, 2022 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3449533 | Jun. 17, 2018 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3449534 | Jun. 17, 2018 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3449535 | Jun. 17, 2018 |
| CNS Research Science, Inc. | CNS COMPREHENSIVE NEUROSCIENCE | 3449536 | Jun. 17, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4156802 | Jun. 12, 2022 |
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4156803 | Jun. 12, 2022 |

| Owner | Mark | Registration Number | Expiration Date |
|----------------------------|---|---------------------|-----------------|
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4156804 | Jun. 12, 2022 |
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4155886 | Jun. 5, 2022 |
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4148011 | May 22, 2022 |
| CNS Research Science, Inc. | COMPREHENSIVE CLINICAL DEVELOPMENT | 4155887 | Jun. 5, 2022 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500478 | Sep. 9, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500479 | Sep. 9, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500480 | Sep. 9, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500481 | Sep. 9, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500482 | Sep. 9, 2018 |
| CNS Research Science, Inc. | COMPREHENSIVE NEUROSCIENCE | 3500483 | Sep. 8, 2018 |
| Radiant Research, Inc. | RADIANT RESEARCH | 2511395 | Nov. 27, 2021 |
| Pharmaco Investments, Inc. | “CG++” | 2,136,203 | Feb. 10, 2018 |
| Pharmaco Investments, Inc. | “CROSSGRAPHS” | 2,084,758 | July 29, 2017 |
| Pharmaco Investments, Inc. | “PPD” (Word Mark) | 2,435,414 | Mar. 13, 2021 |
| Pharmaco Investments, Inc. | “PPD” | 2,332,213 | Mar. 21, 2020 |
| Pharmaco Investments, Inc. | “PPD QUERYDIRECT” | 2,644,316 | Oct. 29, 2022 |
| Pharmaco Investments, Inc. | “TABLETRANS” | 2,179,522 | Aug. 4, 2018 |
| Pharmaco Investments, Inc. | “PRECLARUS” | 4,573,756 | Jul. 22, 2024 |
| Acurian, Inc. | “ACURIAN RECRUITMENT MANAGER” | 3,971,039 | May 31, 2021 |
| Acurian, Inc. | “YOUR PATIENTS HOLD THE PROMISE FOR TOMORROW’S CURES” | 3,723,631 | Dec. 8, 2019 |
| Acurian, Inc. | “CLICK IT FORWARD” | 3,819,261 | Jul. 13, 2020 |
| Acurian, Inc. | “ACURIAN” (Plus Design) | 2,697,439 | Mar. 18 2023 |
| Acurian, Inc. | “ACURIAN” | 2,566,246 | Apr. 30, 2022 |
| Acurian, Inc. | “ACURIAN HEALTH” | 4,411,824 | Oct. 1, 2023 |
| Acurian, Inc. |  [LOGO] | 4,429,550 | Nov. 5, 2023 |

| Owner | Mark | Registration Number | Expiration Date |
|---------------|-----------------------------|---------------------|-----------------|
| Acurian, Inc. | “ACURIAN RETENTION MANAGER” | 4,621,574 | Oct. 14, 2024 |

Trademark Applications

| Owner | Mark | Application Number | Expiration Date |
|----------------------------|-------------|--------------------|-----------------|
| Pharmaco Investments, Inc. | “TRIMENTUM” | 86303607 | N/A |

Schedule C

Registered Copyrights

| Owner | Full Title | Registration Number | Registration Date |
|-----------------------|--|---------------------|-------------------|
| PPD Development, L.P. | PPD Clinical Foundation Program, Volumes I and II, Training Materials, Version February 2009 | TXu001615996 | May 14, 2009 |
| PPD Development, L.P. | Richmond Labs User Guide | TXu001060523 | March 29, 2002 |